Who Paid My Doc
Ali Reza Golshayan
Hematology Gastonia, NC Medical Doctor
NPI 1093990814 CMS profile 1049397
2610 Aberdeen Blvd, Gastonia, NC 28054
General payments
$1,827
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ali Reza Golshayan of Gastonia, NC is reported in the CMS Open Payments database as having received $1,827 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 39th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26 | 1 | |
| 2022 | General | $24 | 1 | |
| 2021 | General | $12 | 1 | |
| 2019 | General | $1,766 | 12 |
Beside peers
- Ali Reza Golshayan
- Hematology median
- Middle half of Hematology
- National median
In program year 2025, general payments to Ali Reza Golshayan were reported at $26. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.
Show as a table
| Year | Ali Reza Golshayan | Hematology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,766 | $1,012 | $122–$9,834 | $163 |
| 2020 | $0 | $1,475 | $115–$9,198 | $114 |
| 2021 | $12 | $1,470 | $125–$7,444 | $132 |
| 2022 | $24 | $1,371 | $139–$8,471 | $149 |
| 2023 | $0 | $1,295 | $147–$11,010 | $160 |
| 2024 | $0 | $1,286 | $146–$9,230 | $164 |
| 2025 | $26 | $1,155 | $135–$8,023 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
986
Drug cost
$1,519,003
Branded share of claims
22.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lenalidomide | Generic | 26 | $318,866 | |
| Imbruvica Ibrutinib | Brand | 29 | $288,656 | |
| Inlyta Axitinib | Brand | 13 | $272,432 | |
| Jakafi Ruxolitinib Phosphate | Brand | 22 | $270,410 | |
| Ibrance Palbociclib | Brand | 15 | $230,465 | |
| Venclexta Venetoclax | Brand | 12 | $58,115 | |
| Eliquis Apixaban | Brand | 74 | $45,992 | |
| Xarelto Rivaroxaban | Brand | 17 | $13,452 | |
| Abiraterone Acetate | Generic | 33 | $7,648 | |
| Imatinib Mesylate | Generic | 23 | $2,139 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 123 billing codesPaid by Medicare
$1,396,309
Medicare patients
276
Services billed
99,863
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 54% | |
| Arthritis | 39% | |
| Chronic kidney disease | 38% | |
| Diabetes | 37% | |
| Ischemic heart disease | 35% | |
| COPD | 26% | |
| Atrial fibrillation | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg Q5111 | Office | 11 | 300 | $33,818 |
| Injection, denosumab, 1 mg J0897 | Office | 11 | 1,560 | $32,192 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 19 | 13,770 | $3,984 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 12 | 5,400 | $596 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 14 | 103 | $533 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 29 | 1,648 | $121 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 24 | 1,170 | $104 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 13 | 76 | $49 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology in North Carolina
Related records
Hematology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Hematology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.